AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
AIMAIM ImmunoTech(AIM) GlobeNewswire News Room·2024-10-03 20:45

OCALA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent No. 12,102,649, covering both compositions and methods comprising the Company’s drug Ampligen® in the treatment of endometriosis, a painful chronic condition that affects nearly 10% of women of reproductive age, or approximately 6.5 million women in the United States. Endometriosis is a disease in w ...